Charles F Jr Wagner Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 5 days, 8 hours ago
Charles F Jr Wagner has an estimated net worth of at least $29.3 million*, as of Jan. 8, 2025. They own 47,137 shares of VRTX stock. They have sold 30,062 shares of VRTX stock since 2021, for an estimated $10.1 million.
Charles F Jr Wagner $VRTX SEC Form 4 Insider Trading
Charles F Jr Wagner has filed a total of 40 insider trades in $VRTX since 2021. Their most recent trade was a sale of 3,250 shares, made on Jun 03, 2024. Their largest trade was a sale of 3,250 shares, made on Jun 03, 2024. We estimate that they now own 47,137 shares of $VRTX, worth an estimated $19.3 million.
Insider Trading at $VRTX
There have been a total of 474 insider trades reported at $VRTX since 2021, with 25,000 shares purchased and 808,928 shares sold. The most active insider traders in $VRTX stock have been David Altshuler, Bastiano Sanna, and Ourania Tatsis. The most recent trade was a sale of 15 shares reported by DAVID ALTSHULER (EVP, Chief Scientific Officer), made on Nov 15, 2024.
History of Insider Stock Trades by Charles F Jr Wagner
Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
---|---|---|---|---|
VRTX | Sale | 3,250 | Jun 03, 2024 | June 5, 2024, 4:11 p.m. |
VRTX | Sale | 3,250 | May 28, 2024 | May 30, 2024, 4:07 p.m. |
VRTX | Sale | 3,000 | Jan 02, 2024 | Jan. 4, 2024, 5:17 p.m. |
VRTX | Sale | 3,000 | Nov 20, 2023 | Nov. 21, 2023, 5:07 p.m. |
VRTX | Sale | 1,768 | Mar 24, 2023 | March 28, 2023, 4:13 p.m. |
VRTX | Sale | 360 | Mar 17, 2023 | March 21, 2023, 4:21 p.m. |
VRTX | Sale | 784 | Mar 17, 2023 | March 21, 2023, 4:21 p.m. |
VRTX | Sale | 16 | Mar 17, 2023 | March 21, 2023, 4:21 p.m. |
VRTX | Sale | 240 | Mar 17, 2023 | March 21, 2023, 4:21 p.m. |
VRTX | Sale | 360 | Mar 17, 2023 | March 21, 2023, 4:21 p.m. |
VRTX | Sale | 240 | Mar 17, 2023 | March 21, 2023, 4:21 p.m. |
VRTX | Sale | 185 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX | Sale | 361 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX | Sale | 515 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX | Sale | 327 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX | Sale | 30 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX | Sale | 541 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX | Sale | 27 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX | Sale | 102 | Mar 10, 2023 | March 14, 2023, 4:22 p.m. |
VRTX | Sale | 24 | Mar 13, 2023 | March 14, 2023, 4:22 p.m. |
VRTX | Sale | 420 | Mar 13, 2023 | March 14, 2023, 4:22 p.m. |
VRTX | Sale | 1,153 | Mar 13, 2023 | March 14, 2023, 4:22 p.m. |
VRTX | Sale | 715 | Mar 13, 2023 | March 14, 2023, 4:22 p.m. |
VRTX | Sale | 292 | Mar 13, 2023 | March 14, 2023, 4:22 p.m. |
VRTX | Sale | 62 | Mar 13, 2023 | March 14, 2023, 4:22 p.m. |
VRTX | Sale | 60 | May 02, 2022 | May 4, 2022, 5:07 p.m. |
VRTX | Sale | 100 | May 02, 2022 | May 4, 2022, 5:07 p.m. |
VRTX | Sale | 20 | May 02, 2022 | May 4, 2022, 5:07 p.m. |
VRTX | Sale | 3 | May 02, 2022 | May 4, 2022, 5:07 p.m. |
VRTX | Sale | 32 | May 02, 2022 | May 4, 2022, 5:07 p.m. |
VRTX | Sale | 48 | May 02, 2022 | May 4, 2022, 5:07 p.m. |
VRTX | Sale | 80 | May 02, 2022 | May 4, 2022, 5:07 p.m. |
VRTX | Sale | 381 | Apr 01, 2022 | April 4, 2022, 8 p.m. |
VRTX | Sale | 300 | Apr 01, 2022 | April 4, 2022, 8 p.m. |
VRTX | Sale | 1,142 | Apr 01, 2022 | April 4, 2022, 8 p.m. |
VRTX | Sale | 536 | Apr 01, 2022 | April 4, 2022, 8 p.m. |
VRTX | Sale | 223 | Apr 01, 2022 | April 4, 2022, 8 p.m. |
VRTX | Sale | 61 | Mar 17, 2022 | March 21, 2022, 4:12 p.m. |
VRTX | Sale | 3,110 | Mar 17, 2022 | March 21, 2022, 4:12 p.m. |
VRTX | Sale | 2,944 | Feb 02, 2022 | Feb. 2, 2022, 8 p.m. |
$VRTX Executives and Stock Owners with Insider Trades
-
David Altshuler, EVP, Global Research and CSO
-
Bastiano Sanna, EVP, Cell & Genetic Therapies
-
Ourania Tatsis, EVP, Chief Reg. & Quality Off.
-
Stuart A Arbuckle, EVP, COO
-
Charles F Jr Wagner, EVP & Chief Financial Officer
-
Jeffrey M Leiden, Executive Chairman
-
Joy Liu, SVP, General Counsel
-
Reshma Kewalramani, CEO & President
-
Carmen Bozic, EVP and CMO
-
Kristen Ambrose, SVP & Chief Accounting Officer
-
Amit Sachdev, EVP Chief Patient & Ext Af Off
-
Edward Morrow Iii Atkinson, EVP, Chief Technical Ops. Off.
-
Amit Sachdev, EVP, Chief Patient Officer
-
Jonathan Biller, EVP and Chief Legal Officer
-
David Altshuler, EVP, Chief Scientific Officer
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.